Misset JL - Search Results

1

An oriented phase II trial of THP-adriamycin in breast carcinoma.

Mathé G, Umezawa H, Oka S, Misset JL, Brienza S, de Vassal F, Musset M, Ribaud P, Tapiero H. Mathé G, et al. Among authors: misset jl. Biomed Pharmacother. 1986;40(10):376-9. Biomed Pharmacother. 1986. PMID: 3580506

2

Immunomodulating properties of bestatin in cancer patients. A phase II trial.

Mathé G, Umezawa H, Misset JL, Brienza S, Canon C, Musset M, Reizenstein P. Mathé G, et al. Among authors: misset jl. Biomed Pharmacother. 1986;40(10):379-82. Biomed Pharmacother. 1986. PMID: 3495299

3

A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP).

Mathé G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL. Mathé G, et al. Among authors: misset jl. Biomed Pharmacother. 1986;40(10):372-6. Biomed Pharmacother. 1986. PMID: 3580505

4

Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.

Machover D, Gastiaburu J, Delgado M, Goldschmidt E, Hulhoven R, Misset JL, de Vassal F, Tapiero H, Dorval T, Ribaud P, et al. Machover D, et al. Among authors: misset jl. Biomed Pharmacother. 1984;38(7):328-31. Biomed Pharmacother. 1984. PMID: 6596962

5

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

Mathé G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, de Vassals F, Chenu E, et al. Mathé G, et al. Among authors: misset jl. Biomed Pharmacother. 1989;43(4):237-50. doi: 10.1016/0753-3322(89)90003-6. Biomed Pharmacother. 1989. PMID: 2675999

6

A phase II trial of immunorestoration with zinc gluconate in immunodepressed cancer patients.

Mathé G, Misset JL, Gil-Delgado M, Musset M, Reizenstein P, Canon C. Mathé G, et al. Among authors: misset jl. Biomed Pharmacother. 1986;40(10):383-5. Biomed Pharmacother. 1986. PMID: 3495300

7

Simultaneous detection in the bone marrow of mammary cancer metastatic cells and of their labelling index as respective markers of the residual minimum submacroscopic disease and its proliferative condition (preliminary results).

Ginsbourg M, Musset M, Misset JL, Genty O, Mathé G. Ginsbourg M, et al. Among authors: misset jl. Biomed Pharmacother. 1986;40(10):386-8. Biomed Pharmacother. 1986. PMID: 3555638

8

Relationship between proliferative activity of bone marrow micrometastasis and plasmatic level of a new cancer marker: lipid associated sialic acid (LASA) in human breast cancer.

Ginsbourg M, Musset M, Misset JL, Mathé G. Ginsbourg M, et al. Among authors: misset jl. Biomed Pharmacother. 1986;40(10):388-91. Biomed Pharmacother. 1986. PMID: 3580507

9

[Treatment of leukemias and lymphomas with interferons: I. Trial of myeloma therapy with human beta-interferon].

Misset JL, Mathé G, Gastiaburu J, Goutner A, Dorval T, Gouveia J, Hayat M, Jasmin C, Schwarzenburg L, Machover D, Ribaud P, De Vassal F, Horosezewicz JS. Misset JL, et al. Biomed Pharmacother. 1982 Jan;36(1):55-9. Biomed Pharmacother. 1982. PMID: 6181822 Clinical Trial. French.

10

[Protocols for the treatment of leukemia and lymphoma: toward escalation or toward reduction of degree?].

Mathé G, Misset JL, Machover D, Schwarzenberg L, Timus M, Jasmin C, Ribaud P, Musset M. Mathé G, et al. Among authors: misset jl. Biomed Pharmacother. 1984;38(1):13-32. Biomed Pharmacother. 1984. PMID: 6380605 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

284 results

Search Page

Filters